Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL 2

NCT04265651 is registered in ClinicalTrials.gov with QED Therapeutics, a BridgeBio company as lead sponsor.

NCT NCT04265651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04265651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL 2
Lead sponsor
QED Therapeutics, a BridgeBio company
Phase
Phase 2
Overall status
Completed
Start date
March 10, 2020
Completion date
October 21, 2024
Enrollment
84 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

achondroplasia